MX2016007170A - Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma). - Google Patents

Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma).

Info

Publication number
MX2016007170A
MX2016007170A MX2016007170A MX2016007170A MX2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A MX 2016007170 A MX2016007170 A MX 2016007170A
Authority
MX
Mexico
Prior art keywords
aml
myeloid leukemia
acute myeloid
combination treatment
novel combination
Prior art date
Application number
MX2016007170A
Other languages
English (en)
Other versions
MX370618B (es
Inventor
Higgins Brian
Nichols Gwen
E Packman Kathryn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016007170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016007170A publication Critical patent/MX2016007170A/es
Publication of MX370618B publication Critical patent/MX370618B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a un producto farmacéutico que comprende: a) como primer componente un inhibidor de la interacción MDM2-p53, y b) como segundo componente, citarabina, como preparación combinada para la utilización secuencial o simultánea en el tratamiento del cáncer, particularmente de la LMA.
MX2016007170A 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma). MX370618B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05
PCT/EP2014/076063 WO2015082384A1 (en) 2013-12-05 2014-12-01 Novel combination treatment for acute myeloid leukemia (aml)

Publications (2)

Publication Number Publication Date
MX2016007170A true MX2016007170A (es) 2016-09-08
MX370618B MX370618B (es) 2019-12-17

Family

ID=52014047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007170A MX370618B (es) 2013-12-05 2014-12-01 Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma).

Country Status (31)

Country Link
US (5) US20160303158A1 (es)
EP (1) EP3077004B1 (es)
JP (3) JP6297695B2 (es)
KR (1) KR101862955B1 (es)
CN (1) CN105792847B (es)
AR (1) AR098576A1 (es)
AU (1) AU2014359422B2 (es)
BR (1) BR112016009669B1 (es)
CA (1) CA2926307C (es)
CL (1) CL2016001345A1 (es)
CR (1) CR20160173A (es)
DK (1) DK3077004T3 (es)
EA (1) EA201690785A1 (es)
ES (1) ES2785203T3 (es)
HK (1) HK1222808A1 (es)
HR (1) HRP20200566T1 (es)
HU (1) HUE049434T2 (es)
IL (1) IL244888B (es)
LT (1) LT3077004T (es)
MA (1) MA39040A1 (es)
MX (1) MX370618B (es)
PE (1) PE20160591A1 (es)
PH (1) PH12016500933A1 (es)
PL (1) PL3077004T3 (es)
PT (1) PT3077004T (es)
RS (1) RS60142B1 (es)
SG (1) SG11201604504VA (es)
SI (1) SI3077004T1 (es)
TW (2) TWI627954B (es)
WO (1) WO2015082384A1 (es)
ZA (1) ZA201602829B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
SI3077004T1 (sl) * 2013-12-05 2020-07-31 F. Hoffmann-La Roche Ag Novo kombinirano zdravilo za akutno mieloično levkemijo (AML)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3344275B8 (en) * 2015-09-03 2023-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
WO2017214014A1 (en) * 2016-06-06 2017-12-14 Celgene Corporation Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ， スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
PL3541387T3 (pl) 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53
RU2753527C2 (ru) * 2017-03-31 2021-08-17 Новартис Аг ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3858361A4 (en) 2018-09-28 2021-12-01 FUJIFILM Corporation ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE
JP2022501394A (ja) * 2019-07-26 2022-01-06 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｍｄｍ２阻害剤の医薬組成物、並びに疾患を予防及び／又は治療するためのその使用
JP2024519335A (ja) * 2021-05-13 2024-05-10 ンカルタ・インコーポレイテッド がん免疫療法のための投薬レジメン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1503757B1 (en) * 2002-05-02 2007-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN101773408B (zh) * 2010-01-15 2012-04-04 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置
SG184288A1 (en) * 2010-04-09 2012-11-29 Univ Michigan Biomarkers for mdm2 inhibitors for use in treating disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
SI3077004T1 (sl) * 2013-12-05 2020-07-31 F. Hoffmann-La Roche Ag Novo kombinirano zdravilo za akutno mieloično levkemijo (AML)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Also Published As

Publication number Publication date
MX370618B (es) 2019-12-17
TWI627954B (zh) 2018-07-01
JP6918724B2 (ja) 2021-08-11
WO2015082384A1 (en) 2015-06-11
CN105792847A (zh) 2016-07-20
US9956243B2 (en) 2018-05-01
CR20160173A (es) 2016-06-08
SG11201604504VA (en) 2016-07-28
US20200253999A1 (en) 2020-08-13
IL244888A0 (en) 2016-05-31
EP3077004A1 (en) 2016-10-12
AU2014359422B2 (en) 2020-03-05
TWI678204B (zh) 2019-12-01
AU2014359422A1 (en) 2016-04-28
PL3077004T3 (pl) 2020-08-10
BR112016009669B1 (pt) 2023-01-24
US20220031726A1 (en) 2022-02-03
BR112016009669A8 (pt) 2020-04-07
HUE049434T2 (hu) 2020-09-28
US20150157603A1 (en) 2015-06-11
ZA201602829B (en) 2017-04-26
EP3077004B1 (en) 2020-02-19
JP2016539160A (ja) 2016-12-15
KR101862955B1 (ko) 2018-05-31
PT3077004T (pt) 2020-04-16
PE20160591A1 (es) 2016-06-11
AR098576A1 (es) 2016-06-01
DK3077004T3 (da) 2020-04-27
RS60142B1 (sr) 2020-05-29
IL244888B (en) 2020-11-30
CA2926307C (en) 2021-11-16
HK1222808A1 (zh) 2017-07-14
ES2785203T3 (es) 2020-10-06
SI3077004T1 (sl) 2020-07-31
CA2926307A1 (en) 2015-06-11
US20230381215A1 (en) 2023-11-30
LT3077004T (lt) 2020-05-11
EA201690785A1 (ru) 2016-10-31
JP2018111700A (ja) 2018-07-19
JP2021091690A (ja) 2021-06-17
PH12016500933A1 (en) 2016-06-27
HRP20200566T1 (hr) 2020-06-26
CN105792847B (zh) 2019-11-08
TW201840310A (zh) 2018-11-16
US20160303158A1 (en) 2016-10-20
TW201526890A (zh) 2015-07-16
CL2016001345A1 (es) 2017-04-07
KR20160070190A (ko) 2016-06-17
JP6297695B2 (ja) 2018-03-20
MA39040A1 (fr) 2018-01-31

Similar Documents

Publication Publication Date Title
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
TW201614068A (en) Fucosidase from bacteroides and methods using the same
MX2020009919A (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2016001683A (es) Combinaciones de inhibidores de quinasa pim.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX370673B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
WO2014177464A3 (en) Inhibitors of nhr2 and/or runx1/eto-tetramerization
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
NZ717192A (en) Anti-inflammatory tripeptides
MX2015016603A (es) Composiciones de corticosteroides.
WO2015027121A3 (en) Cancer treatment
MX356102B (es) Compuestos y métodos para tratar leucemia.
PH12017501979A1 (en) Pharmaceutical compound
IN2014MU00495A (es)
NZ725303A (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
MX2015013736A (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemia por deficiencia de hierro.

Legal Events

Date Code Title Description
FG Grant or registration